Gilead Sciences, Inc. (GIS.DE)
Develops medicines to treat HIV, hepatitis, cancer, and other serious diseases.
117.92+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+21.3%
The outlook
Gilead Sciences is trading above both its 50- and 200-day moving averages, positioning it in the upper half of its 52-week range. Analyst sentiment leans bullish overall. The stock carries a trailing P/E of 18.2, reflecting current valuation relative to recent earnings.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range64% of the way from its 52-week low to high
Market cap
$146.41B
52-wk high
132.00
52-wk low
92.41
50-day avg
112.78
200-day avg
113.57
Trailing P/E
18.2